Participated · Series B · Aug 2026

Amplifica is a clinical-stage biopharmaceutical company focused on developing injectable therapies aimed at reactivating dormant hair follicles and promoting new hair growth. The company has built a proprietary portfolio of signaling molecules that regulate the hair follicle growth cycle and said its candidates activate follicle regeneration through distinct, complementary mechanisms of action. Amplifica will be initiating product development programs and clinical trials to evaluate safety and efficacy and to seek regulatory approvals. The company’s currently marketed products are primarily intended to slow or prevent further hair loss, while the pipeline targets regeneration. Amplifica raised $26 million in an oversubscribed Series B Preferred Stock financing to fund its clinical development plans. The company is based in San Diego and is addressing androgenetic alopecia, a condition the company notes affects over 50 million men and over 30 million women in the United States.

Led · Series E · Jun 2023

Founded in 2005 by college roommates Steven Katz and Dr. Jeffrey Schor and based in Long Island, New York, PM Pediatric Care operates pediatric urgent care centers and provides telemedicine and school-based virtual physical and mental health services. The company has treated 6.5 million patients and operates 78 locations across 15 states. It generates revenue primarily through insurer reimbursement and accepts most health plans. PM Pediatric Care has expanded its service lines to include behavioral health and telehealth and plans to add primary care. Leadership says the company intends to grow site count—particularly in markets where it already has a presence such as Chicago, Los Angeles and Dallas—and to build out its behavioral health business. Management is also exploring acquisitions and a shift toward value-based care, requiring investment in outcome-tracking systems.

Participated · Equity · Nov 2017

Y-mAbs is a clinical-stage biopharmaceutical company focused on immunotherapies for cancer, with lead antibody programs targeting GD2 and B7-H3. Its pipeline includes two lead compounds, burtomab and naxitamab, and platform technologies to create humanized, affinity-matured bispecific antibodies. The company is collaborating on a novel human protein tag that dimerizes T-cell engaging bispecifics to improve tumor binding, extend serum half-life, and increase T-cell–mediated tumor cell killing. Y-mAbs aims to drive multiple product candidates in select solid tumors to FDA approval and to reduce long-term toxicities compared with existing chemotherapies. The company plans to advance its next wave of candidate medicines into clinical trials and to build commercial organization and sales and marketing capabilities as programs near approval.

Participated · Equity · Dec 2013

Zalora is an online fashion and beauty retailer operating across Southeast Asia, including Brunei, Hong Kong, Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. Since its inception in 2012, ZALORA offers more than 130,000 products and over 500 international brands and is described as the region's leading online fashion & beauty retailer. Management says it will use new investment to grow assortment, enhance private-label offerings, and improve customer experience as it seeks to solidify its position as the high-street fashion authority in Southeast Asia. The company is targeting expansion to serve the region's expanding middle class and roughly 600 million potential online shoppers. Specific revenue or profitability figures are not disclosed in the article. Zalora is a Zappos‑style fashion e-commerce site backed by Rocket Internet and the Samwer brothers, headquartered in Singapore and operating in Singapore, Indonesia, Malaysia, Brunei, the Philippines, Thailand, Vietnam, Taiwan and Hong Kong. The site carries roughly 500 brands and about 20,000 products per country site and recently delivered its one millionth order. The company reports "double-digit million USD revenues" and says mobile sales comprise 25% of total sales. Since launching in March 2012, Zalora has used prior funding to build out its footprint, invest in logistics and in R&D, and to develop new platforms such as an iOS app. Management has changed since launch and is currently led by Michele Ferrario. The company is focused on continued geographic expansion and scaling backend and logistics to reach a growing online middle class in emerging markets. Zalora is an online fashion and beauty e-tailer backed by Rocket Internet that sells apparel and beauty products across Singapore, Indonesia, Malaysia, the Philippines, Thailand, Vietnam, Hong Kong and Taiwan. The company is building a regional software development center in Singapore to develop its web platform and mobile apps. Since its launch early last year, Zalora says it has achieved 'annualized double-digit million' revenues and now employs more than 1,000 people. Zalora has pursued strategic partnerships and investment to support expansion and software innovation. Its relationship with Rocket Internet and new strategic investors is positioned to help scaling, retail partnerships and margin improvements. Zalora operates an online fashion and lifestyle marketplace offering more than 300 brands across men’s, women’s and children’s clothing and home accessories. The site provides free shipping, a 30-day return policy and a cash-on-delivery payment option. Launched in early 2012 and based in Singapore, Zalora quickly expanded to eight markets across Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam. The company employs roughly 1,000 people and has already achieved annualized double-digit million USD revenues. Management and investors are positioning the business for continued regional expansion to capture a potential market of roughly 500 million users. Recent strategic investment from J.P. Morgan Asset Management is intended to support further growth and expansion across its footprint.